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Abstract: 
Multiple Myeloma (MM) is an incurable hematologic malignancy characterized by abnormal 
proliferation of plasma cells. Interferon Regulatory Factor 4 (IRF4), a member of the interferon 
regulatory family of transcription factors, is central to the genesis of MM. IRF4 is highly expressed 
in B cells and plasma cells where it plays essential roles in controlling B cell to plasma cell 
differentiation and immunoglobulin class switching. Overexpression of IRF4 is found in MM 
patients’ derived cells, often as a result of activating mutations or translocations, where it is 
required for their survival. In this review, we first describe the roles of IRF4 in B cells and plasma 
cells and then analyse the subversion of the IRF4 transcriptional network in MM. Moreover, we 
discuss current therapies for MM as well as direct targeting of IRF4 as a potential new therapeutic 
strategy. 
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1. Introduction 
Multiple Myeloma (MM) is an aggressive and incurable bone marrow cancer characterized by the 
clonal proliferation of malignant plasma cells (PCs), the presence of monoclonal antibodies in the 
blood or urine and organ dysfunction [1]. MM represents approximately 2% of all cancers and 
about 10% of all hematologic malignancies [2] with a rising incidence estimated to be 6-10 cases 
per 100,000 persons per year. In the UK alone 5540 people were diagnosed and 3079 deaths 
were reported in 2016 by. The median age of patients at the time of diagnosis is about 65 years 
[2]. MM is considered a multistep disease since almost all patients with MM are characterized by 
an asymptomatic pre-malignant stage termed monoclonal gammopathy of undetermined 
significance (MGUS) and some patients by an intermediate asymptomatic but more advanced 
pre-malignant stage called smouldering multiple myeloma (SMM) [2] [3]. Both MGUS and SMM 
are characterized by the presence of the same chromosomal abnormalities of MM without clinical 
manifestations [3]. Moreover, MGUS evolves in MM in 1% of cases per year, while SMM 
progresses to MM in 10% of cases per year for the first 5 years following diagnosis [2].  
Novel immunomodulatory drugs such as thalidomide and lenalidomide and proteasome inhibitors 
such as bortezomib, together with autologous stem cell transplantation when possible, have 
dramatically improved the median overall survival of patients. Relapse however will occur in all 
myeloma patients and the median overall survival following resistance to both bortezomib and 
thalidomide or lenalidomide is 9 months [4]. There is a clear need for new treatment approaches 
that would be able to overcome a dismal course of the disease in these patients.  
Interferon Regulatory Factor 4 (IRF4) is a transcription factor belonging to the interferon regulatory 
factor (IRF) family. IRFs are transcription factors playing a critical role in the regulation of immune 
responses, immune cell development, cell growth regulation and metabolism [5]. IRF4 is a critical 
regulator of the immune system and it is essential for PC differentiation [6] [7]. IRF4 has also 
emerged as the master regulator of an aberrant and malignancy-specific gene expression 
  
programme in MM, where it is found to be overexpressed often as a result of activating mutations 
or translocations [8]. Knockdown experiments of IRF4 have shown a dramatic decrease in the 
viability of MM cells [8]. Yet IRF4 has not been the direct target of therapeutic drug discovery 
programmes.  
Here we describe the role of IRF4 during normal PC differentiation, the mechanism of IRF4-driven 
deregulation of transcriptional activity in MM and we discuss the value of new therapeutic avenues 
to treat MM, including the direct targeting of IRF4. 
 
2. IRF4 structure and transcriptional activity 
IRF4 is characterized by an N-terminal tryptophan pentad repeat DNA-binding domain (DBD) 
connected to a C-terminal interferon activation domain (IAD), critical in mediating protein-protein 
interactions via a linker domain (LKD) (Fig.1) [5]. The DBD domain resembles a winged helix-
turn-helix motif with a 3-helix bundle (α1, α2, α3), a 4-stranded antiparallel beta-sheet (β1-β4) and 
two large loops (between β2 and α2 and α2 and α3) (Fig.1b). The third helix slots into the major 
groove of the 5′-GAAA-3′ subsequence and is the major determinant of sequence-specific binding 
through contacts made by arginine residues on the hydrophilic face with the phosphate backbone 
(Fig.1b). Three of the five invariant tryptophan residues contact DNA [9] [5]. 
Interestingly however, and unlike other IRF protein, IRF4 binds DNA with low affinity and requires 
further protein-protein interactions to bind DNA.  IRF4 is essential for the expression of both GC 
B cell-specific and PC-specific genes and the low affinity for DNA is thought to be central to this 
role. Depending on its protein levels, IRF4 binds DNA as a heterodimer or a homodimer to 
different motifs, each motif uniquely activating the expression of genes related to GC B-cell or PC 
differentiation. At low protein levels, IRF4 binds as a heterodimer either the AP-1-IRF composite 
elements AICEs (GAAATGAGTCA or GAAANNNNTGAGTCA) with AP-1 family such as Batf  
  
(Fig.2a,d) or the Ets-IRF composite elements EICEs (GGAANN(N)GAAA) with PU.1 (Fig.2b,e) 
[10] [11]. During the differentiation of B cell into PCs protein levels increase and IRF4 binds as a 
homodimer to the interferon sequence response elements ISREs (GAAANNGAAA) [12] (Fig.2c, 
f). 
The low DNA binding affinity of IRF4 has been attributed to the inhibitory activity of the last 30 
residues of the IAD domain [13] [10] (Fig.1a). It has been postulated that this auto-inhibitory region 
(AR) prevents the DBD from binding to DNA, whilst DBD interactions with transcription factor 
partners would release AR inhibition [10]. This hypothesis however does not explain how release 
of the inhibition would occur when IRF4 binds to ISRE sequences as a homodimer. Recent 
structural studies have shown that the AR region is a flexible unstructured peptide that does not 
dock into the IAD helical bundle, as seen in IRF3 [5] [14] [15]. Furthermore, the diversity in 
sequence homology and length of the IRF4 AR region, suggest that alternative mechanisms could 
induce IRF4 dimerization on DNA. SAXS studies of full length IRF4 suggests that the linker region 
(LKD) connecting the DBD and IAD domains most likely adopts a folded conformation able to 
interact with the domains located at either end of the molecule and that it may therefore play a 
role in the regulation of IRF4 activity [5] (Fig.1b).  
 
3. IRF4 role in transcriptional circuitry of GC B cells and plasma cells 
IRF4 is the master regulator of two mutually antagonistic programs of B and PC cells gene 
expression [12]. B cells play a fundamental role in the humoral immune response. During antigen-
dependent activation, B cells can rearrange the constant region of the IgH region yielding 
antibodies with different effector functions by a process called class-switch recombination (CSR). 
Moreover, after antigen-dependent activation, mature B cells undergo to somatic hypermutation 
(SHM), a process that alters the variable regions of the immunoglobulin in order to select B cells 
  
producing high affinity antibodies. SHM leads to the affinity maturation of B cells in germinal 
centres (GCs) that are transient structures within secondary lymphoid organs where B cells are 
selected based on their ability to produce high-affinity antibodies [16]. GCs are characterized by 
two compartments: the dark zone (DZ) where B cells proliferate extensively undergoing SHM and 
the light zone (LZ) in which B cells are selected on the basis of their affinity for the antigen. The 
GCs ultimately produce memory B cells and high-affinity, long-lived PCs characterized by high 
level of antibody secretion [17]. Molecular alterations occurring during early and late phases of B 
cell development can lead to the generation of lymphoid tumours.  
According to the ‘’kinetic model’’ proposed by Ochiai et al, [12] IRF4 regulates CSR, SHM, the 
generation of GC B cells and PC differentiation in a temporal and dose-dependent manner [7] [6] 
[12]. Specifically, in the early stages of the GC reaction low levels of IRF4 and binding to AICE 
and EICE motifs contributes to AID expression, which is absolutely necessary for CSR and SHM 
[18], as well as activation of Bcl6, a key regulator of GC formation and maintenance (Fig.3a) [12] 
[19]. On the other hand, during PC differentiation lRF4 levels are elevated and favour binding of 
IRF4 to the ISREs of direct target genes such as Prdm1, leading to expression of Blimp1. The 
shift to ISREs binding therefore mediates activation of Blimp1, a key component of the PC 
differentiation transcription programme [20] [21], and repression of Bcl6, bringing the GC program 
to and end and promoting the differentiation into PCs (Fig 3b,c). IRF4 levels appear to define cell 
fate decisions by coordinating binding partner- and DNA-binding activity. 
IRF4 is absolutely required for GC formation. Studies looking at the effect in mice of B-cell specific 
knockdown of IRF4, show a failure in GC formation caused by insufficient induction of Bcl6 and 
AID [12] [7] [6]. Bcl6 is able to control a large transcriptional network by repression [22]. Bcl6, 
which is highly expressed in GC B cells, facilitates their rapid proliferation in the dark zone through 
repression of cell cycle controlling genes, such as p53 and p21, and through inhibition of the DNA 
damage response that facilitates tolerance for high rates of SHM [23]. In vivo studies have shown 
  
that transient expression of IRF4 directly activates but does not maintain Bcl6 expression in GC 
B cells [12], suggesting that IRF4 might play an essential role for the establishment but not for the 
maintenance of GC state. Evidence suggests that IRF4 might itself be down regulated by Bcl6 in 
GC B cells [24]. 
Once the germinal centre is formed, IRF4 expression needs to be inhibited to avoid premature 
differentiation into PCs [12] [19], however the exact mechanism by which this occurs is unknown. 
In vivo studies showed that during germinal centre B-cell differentiation Bcl6 represses Blimp1 
expression in cooperation with Bach2, a transcriptional repressor expressed during B cell 
differentiation (Fig.3a,b) [25]. Specifically, Bcl6 and Bach2 cooperate in regulating B cells GC 
transcriptional program by forming a complex and recruiting each other to their respective PDRM1 
DNA binding sites [25]. Moreover, in vivo studies showed that Bcl6 directly inhibits Myc expression 
and confirmed the absence of Myc expression in the centroblasts located in DZ of the GC (Fig.3b) 
[26] [27]. Myc repression in active proliferating DZ B cells may explain the reduced number of cell 
divisions in DZ which allows for the affinity maturation process in the DZ of the GC [26]. On the 
other hand Myc is expressed in LZ GC B cells to enable their re-entry into the DZ and the 
continuation of the GC reaction (Fig.3b) [26].  
During PC differentiation, high levels of IRF4 induce Blimp1 expression and together they repress 
Bcl6 expression to terminate the GC program (Fig.3b) [20] [21] [28]. Once the differentiation of 
PCs has taken place, Blimp1 enhances IRF4 expression and represses Myc transcription causing 
an arrest in the PC cell cycle, as Myc is required for cell proliferation and growth (Fig.3c) [7] [28] 
[29]. In addition, the expression of the master regulator of B cell identity Pax5, regulated by IRF4 
and regulating IRF4, Bach2 and AID expression during B-cell development (Fig.3a) is inhibited 
by Blimp1 once differentiation of PCs takes place (Fig.3c) [30] [31] [32] [33]. The Blimp1-mediated 
inhibition of Pax5 causes in turn expression of X-box binding protein 1 (XBP1), a transcription 
factor required for PC development, which induces Unfolded Protein Response (UPR) target 
  
genes [33] (Fig.3c). In PCs, the UPR functions as a physiological pathway and it is activated 
during the early differentiation that precedes the high immunoglobulin expression [34]. 
Recently, a novel mechanism of IRF4-dependent gene repression during PC differentiation 
involving newly identified DNA binding motifs called ZICE, was described [35]. Zinc finger–IRF 
composite elements ZICE (GGGAANNNGAAA), composed of the zinc finger motif (GGGAA) and 
the IRF motif (GAAA), embed an ISRE motif which allows IRF4 to bind the ZICE sequence as a 
heterodimer with Ikaros or the ISRE sequence as a homodimer. Surprisingly, and despite the high 
levels of IRF4 during PC differentiation, IRF4 is more efficiently recruited to ZICE motifs in the 
presence of Ikaros. Crucially, the ZICEs were identified among a subset of IRF4 target genes 
whose expression is reduced upon PC differentiation, including Ebf1 a positive regulator of B-cell 
activation and GC reactions [35]. This report expands the number of transcription factors that 
partner with IRF4 to orchestrate GC B-cell and PC differentiation and raises the question of how 
the delicate balance of transcription factors is accurately sustained. 
 
4. IRF4 and Multiple Myeloma 
4.1 IRF4 transcriptional network in Multiple Myeloma 
IRF4 plays a central role in the pathogenesis of MM [8]. Chromosomal translocation 
t(6;14)x(p25;q32), which juxtaposes the immunoglobulin heavy-chain (IgH) locus to IRF4, is 
recurrently found in about ~21% of MM cases [36] [37]. Sequencing of paired tumour/normal 
samples from 203 MM patients found four IRF4 missense mutations, with three of the mutations 
being identical (K123R) establishing K123R as a recurrent, “hot spot” mutation in IRF4 [38] [39]. 
IRF4 is highly expressed in MM patients when compared to healthy PCs [40]. Moreover, IRF4 is 
an important prognostic marker for MM with longer survival in patients with low IRF4 expression 
[40]. MM tumours are however known to be highly heterogeneous and IRF4 is overexpressed 
  
without genetic alterations in many MM cases [8]. In the context of MM, IRF4 is known to up-
regulate over 100 genes that are quiescent in healthy PCs. Most of these genes, among them 
Stag2, CDK6, and Myc are associated with cellular growth and survival [8]. A study utilizing small 
hairpin RNAs (shRNAs) showed that IRF4 silencing results in loss of cell viability in 10 different 
MM cell line models (representing different MM subtypes most of them lacking IRF4 genetic 
abnormalities) suggesting that MM cells depend on the ability of IRF4 to sustain an aberrant gene 
transcription programme [8]. This dependency has led to proposal of the “non-oncogenic 
addiction” of MM cells to IRF4 where the aberrant functions of normal genes, which themselves 
are not classical oncogenes, is required for cancer cells survival [8] [41]. 
ChIP-chip analysis showed that the regulatory network that IRF4 controls in MM includes genes 
involved in many cellular process like cell cycle regulation, membrane biogenesis, cell death 
regulation, PC function [8]. This regulatory network does not reflect the genetic program of normal 
PCs and instead more closely resembles that of antigen stimulated mature B cells [8]. Since MM 
is characterized by many epigenetic alterations [42], this landscape could allow IRF4 access to 
loci that are usually not accessible in normal PCs [8]. 
A direct IRF4 target of particular interest in MM is KLF2, a transcription factor of the Krϋppel zinc-
finger family, a negative regulator of pre-B cell clonal expansion and B cell activation [43] (Fig.3d). 
Ohguchi et al. showed that knockdown of KLF2 caused apoptosis of MM cell lines indicating that 
KLF2, like IRF4, is essential for MM cells [44] [8]. Interestingly, later studies demonstrated that 
KLF2 and IRF4 are activated by, and in turn activate, KDM3A a member of the Jumonji C-domain-
containing histone demethylases, which catalyses the removal of H3K9 mono- and dimethylation 
(H3K9me1 and H3K9me2) [45]. The KDM3A–KLF2–IRF4 auto positive feedback loop was shown 
to be important for MM cell survival and homing to the bone marrow [44]. As KDM3A regulates 
KLF2 and IRF4 expression through its H3K9 demethylation activity, targeting the enzymatic 
activity of KDM3A could therefore open an interesting therapeutic window [44]. 
  
Another direct target of IRF4 in MM is Myc (Fig.3d) [8]. Unexpectedly, IRF4 itself is also a direct 
target of Myc transactivation, generating an auto regulatory circuit in MM (fig.4). [8]. Moreover, 
ChiP assay experiments showed that IRF4 and Myc regulate each other in MM cell lines, creating 
a positive regulatory loop resulting in an aberrant proliferation of MM cells [8] (Fig.3d). Myc 
expression in MM cells is unusual since normal PCs do not express Myc due to repression by 
Blimp1 [29] [46] (Fig.3c). Gyory et al. and Ocana et al. reported that MM cell lines overexpressed 
an alternative isoform of Blimp1, called Blimp1β, when compared to normal PCs [47] [48]. Blimp1β 
lacks the first 101 amino-terminal residues [47] and has a disrupted PR domain, a domain with 
similarities to SET domains found in Histone methyltransferases [47] [49]. In addition, Blimp1β is 
characterized by a diminished capacity to repress target genes, like Myc [47]. The expression of 
the truncated protein Blimp1β could explain the inability of Blimp1 to silence Myc in MM cells.  
Similarly, Bcl6 that does not normally express in healthy PCs because of inhibition by Blimp, is 
instead up regulated in MM cells in the bone marrow microenvironment [20] [50] (Fig.3d). Bcl6 
over expression in MM cells, which is modulated at least in part via Janus kinase/STAT3 and 
canonical nuclear factor-κB pathways, can attenuate the DNA Damage Response, conferring a 
selective advantage to MM cells growth [50] [51]. 
 
4.2 Targeting the IRF4 Transcriptional Network in Multiple Myeloma 
Multiple myeloma (MM) is a clonal PC malignancy characterized by the growth of tumour cells in 
the bone marrow and an aggressive clinical course [52]. During the past decade, the advent of 
proteasome inhibitors (like bortezomib) and immunomodulatory agents (like lenalidomide) has 
improved the treatment of MM [53], however it remains an incurable disease. Almost all patients 
with MM who survive initial treatment will eventually relapse and require further therapy [53]. 
Given that MM cells depend on IRF4 for survival, blocking its expression or interfering with its 
  
transcriptional network might be attractive and broadly applicable therapeutic options for the many 
subtypes of multiple myeloma [8] (Fig.4). 
One way to target IRF4 is through its upstream epigenetic regulators. Conery et al. reported that 
inhibition of the transcriptional coactivators CBP/EP300 via its bromodomain selectively 
abrogates the viability of multiple myeloma cell lines as a result of direct transcriptional 
suppression of IRF4 and of its target genes [54]. In particular, CBP/EP300 bromodomain inhibition 
caused down-regulation of Myc, suggesting that CBP/EP300 plays an important role in the 
regulation of the IRF4/Myc axis in MM [54]. Alzrigat et al. showed that the inhibition of the catalytic 
subunit EZH2 of the polycomb repressive complex 2 (PRC2) causes a reduction of MM cells 
viability and a down regulation of IRF4, Myc and Blimp1 expression via upregulation of potent 
tumour suppressor microRNAs miR-125a-3p and miR-320c [55]. 
Alternatively, direct transactional activators upstream of IRF4 could be targeted. 
Immunomodulatory drugs (IMiDs) like lenalidomide and thalidomide have been shown to have 
potent anti-tumour activities in MM resulting from IMiDs/Cereblon-mediated selective degradation 
of transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which are direct transcriptional 
regulators of IRF4 [56] [57] [58]. 
Growing experimental and clinical evidence underscore the importance of natural killer (NK) cells 
in the immune response against MM. Combination therapies that also enhance the activity of NK 
cells against MM are showing promise in treating this hematologic cancer. For example, inhibition 
of BET through its bromodomain causes an increase of NK cell-activating MICA ligand in MM 
cells resulting in enhanced NK cell-mediated cytotoxicity and an upregulation of the tumour 
suppressor microRNA-125b-5p (miR-125b), involved in the downregulation of IRF4 expression 
and of its downstream signalling [59] [60]. Incidentally, IMiD drug lenalidomide has both 
tumouricidal and immunomodulatory activity in MM as the Cereblon-dependent degradation of 
IKZF1/3 proteins also causes an increase of NK cell-activating ligands MICA and PVR  [61]. 
  
Given the importance of the MM- specific auto regulatory loop between IRF4 and Myc [8], IRF4 
could be down regulated by direct targeting of Myc. Previous studies show that knockdown of 
Myc results in a decreased viability of MM cells [8], whilst inhibition of Myc-Max 
heterodimerization, by the small-molecule compound 10058-F4, causes MM cell death [62]. Since 
BET protein BRD4 directly regulates Myc expression in MM cells [63] [64], treatment of MM cells 
with BET inhibitor JQ1 causes release of BRD4 from the Myc promoter resulting in the reduction 
of proliferation and viability of MM cells [63] [64]. Incidentally, BET inhibitor JQ1 also suppresses 
the secretion of the key survival factor IL-6 in MM cells [65]. 
Another strategy to target IRF4 could be to disrupt MM-specific IRF4 direct protein-protein 
interactions, although it is not clear if IRF4 directly interacts with other protein in the MM context. 
Co-occupancy of EICE composite motifs sites by PU.1 and IRF4 is important for gene regulation 
during B cell activation [12]. During PC differentiation however high concentrations of IRF4 
promote binding to ISRE motifs, upregulating PC specific genes, like PDRM1, and inhibiting PU.1 
(Spib1) [12] [20]. In the majority of MM cells studied, PU.1 has been shown to be down regulated 
[66], however induced overexpression of PU.1 in MM cells causes down regulation of IRF4 
expression and cell death by activation of the IRF7-INFβ pathway [67]. Up regulation of PU.1 
could therefore represent a promising therapeutic strategy for MM. 
The MM specific IRF4 aberrant downstream transcriptional network could also represent a valid 
target for inhibition.  Previous studies reported that knockdown of Blimp1 by short hairpin RNA 
causes apoptosis in MM cells [68] and that the interaction between Ailos and Blimp1 plays an 
important role in MM cells survival, probably through the collaborative down-regulation of pro-
apoptotic genes [69]. Moreover, treatment with IMiD lenalidomide caused proteasomal 
degradation of Blimp1 and reduced Aiolos levels leading to apoptosis of MM cells [69]. 
MM cells secrete an excess of monoclonal proteins and a stringent endoplasmatic reticulum (ER) 
quality control is essential for these high levels of protein synthesis [70]. During ER stress, 
  
activated IRE1α protein mediates splicing of the XBP1 mRNA and fully initiates the UPR [71]. 
Because of its fundamental role in ER quality control, Xbp1 is highly expressed in MM cells and 
is required for their growth and survival [70]. Mimura et al. showed that targeting the IRE1α-Xbp1 
pathway by small-molecule inhibition results in a decrease of MM cell viability [70]. Moreover, 
IRE1α-Xbp1 pathway inhibition in MM cells causes an enhanced activity of the proteasome 
inhibitor (PI) drug bortezomib [70]. 
5. Summary and future directions 
Despite the introduction of novel immunomodulatory drugs, such as thalidomide and lenalidomide 
and proteasome inhibitors such as bortezomib, MM remains an incurable cancer. In this review, 
we firstly examined the biology of IRF4 in healthy B cells and PCs and we then focused on the 
aberrant IRF4-transcriptional network, characteristic of MM cells. Knockdown experiments and 
pharmacological suppression have both shown significant decrease in the viability of MM cells [8] 
[54] confirming IRF4 as an attractive target for novel therapeutic strategies (Fig.4).. Various 
pharmacological approaches have been discussed based on the inhibition of IRF4 MM-specific 
upstream and downstream pathways. 
Future work might focus on the direct inhibition of IRF4, as currently no IRF4-specific small 
molecule inhibitor is available. Concentration induced homodimerization and consequent binding 
to ISRE composite motifs has been shown to be a requirement for IRF4 to mediate its 
transcriptional activity in the context of PCs [12]. Overexpression in MM suggests that 
homodimerization is the prevalent IRF4 mode of action in MM cells and that targeting such 
dimerization could constitute a valid approach to MM subversion. This hypothesis is arguably 
validated by the observation that mice with only one Irf4 allele are phenotypically normal, whilst 
50% decrease of IRF4 at both the mRNA and protein levels causes MM cell death [8] [72]. An 
IRF4-directed therapy could therefore kill MM cells with little or negligible effect effects on normal 
cells making it potentially an exciting therapeutic avenue for MM patients. 
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Figure Legends 
Figure 1: Overall structure of IRF4. (a) Schematic representation showing the domain 
arrangement of IRF4: DNA binding domain (DBD, red), linker domain (LKD), Interferon Activating 
Domain (IAD, blue), auto inhibitory region (AR). (b) Cartoon representation of the crystal structure 
of the IRF4 DBD bound to GAAA consensus motif [9] and IAD (PDB: 5BVI). The LKD domain, 
which is thought to be folded into a domain structure, interacts with both DBD and IAD domains 
[5]. The AR domain is flexible and does not interact with either IAD or DBD domains [5]. 
  
Figure 2: IRF4 cooperative DNA binding and transcription outcome. (a, b, c) Schematic 
representation of the different IRF4 DNA binding modes. IRF4 binds the affinity high affinity 
composite DNA binding motif ETS–IRF (EICE) with members of the Ets family (a) or AP-1-IRF 
(AICE) with members of the AP-1 family (b). At high concentrations IRF4 binds the DNA interferon 
response elements (ISRE) as a homodimer (c). The different outcomes of cooperation between 
IRF4 and other transcription factors or itself are listed. The crystal structure of the PU.1 (teal) - 
IRF4 (red) DNA binding domains bound on a high affinity EICE composite motif is shown in a 
cartoon representation (d). A model of the BATF-Jun (green) - IRF4 (red) DNA binding domains 
complex bound on an AICE motif (e), based on the known structures of the Jun-ATF2-IRF3B 
complex in the interferon-β enhanceosome (PDB: 1T2K) and the PU.1-IRF4 complex on the IgL 
λ gene enhancer [9], is shown in a cartoon representation. The model was built using AICE motifs 
from Bcl11b (0 bp spacing) loci. A model for the IRF4 DNA binding domain homodimer (red) 
bound on an ISRE motif (f) based on the structure of the PU.1-IRF4 complex on the IgL λ gene 
  
enhancer [9] is shown in a cartoon representation. The model was built using an ISRE motif with 
2bp spacing. 
 
Figure 3: IRF4-transcriptional networks in activated B cells, Germinal Centers, Plasma 
Cells and Multiple Myeloma Cells. Schematic representation of IRF4-transcriptional networks 
where green and boxes denote actively expressed and repressed protein respectively (a) 
Schematic representation of the IRF4-transcriptional network in activated B cells where IRF4 is 
expressed at low levels (*). (b) Schematic representation of the IRF4-transcriptional network in 
GCs. IRF4 is not expressed in the Dark Zone whilst it is expressed at high levels (**) in the Light 
Zone. (c) Schematic representation of the IRF4-transcriptional network in a plasma cells where 
IRF4 is expressed at high level (**). (d) Schematic representation of the aberrant IRF4 
transcriptional network in myeloma cells where IRF4 is overexpressed (**). 
 
Figure 4: Targeting the IRF4-transcriptional network in Multiple Myeloma Cells. (a) High 
levels of IRF4 drive the differentiation of activated B cells into plasma cells. (b) Aberrant 
overexpression of IRF4 drives and the development of myeloma cells. (c) Myeloma cells are 
addicted to an abnormal regulatory network controlled by IRF4 and IRF4 inhibition leads cells to 
apoptosis. 
  
  
 
  
  
 
  
  
 
  
  
 
